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Short-term inhibition of TERT induces telomere
length-independent cell cycle arrest and apoptotic
response in EBV-immortalized and transformed B cells
Andrea Celeghin1, Silvia Giunco1, Riccardo Freguja1, Manuela Zangrossi1, Silvia Nalio2, Riccardo Dolcetti3,4 and Anita De Rossi*,1,2
Besides its canonical role in stabilizing telomeres, telomerase reverse transcriptase (TERT) may promote tumorigenesis through
extra-telomeric functions. The possible therapeutic effects of BIBR1532 (BIBR), a powerful TERT inhibitor, have been evaluated in
different cellular backgrounds, but no data are currently available regarding Epstein–Barr virus (EBV)-driven B-cell malignancies.
Our aim was to characterize the biological effects of TERT inhibition by BIBR on EBV-immortalized lymphoblastoid cell lines (LCLs)
and fully transformed Burkitt’s lymphoma (BL) cell lines. We found that BIBR selectively inhibits telomerase activity in TERT-
positive 4134/Late and 4134/TERT+ LCLs and EBV-negative BL41 and EBV-positive BL41/B95.8 BL cell lines. TERT inhibition led to
decreased cell proliferation, accumulation of cells in the S-phase and ultimately to increased apoptosis, compared with mock-
treated control cells. All these effects occurred within 72 h and were not observed in BIBR-treated TERT-negative 4134/TERT- and
U2OS cells. The cell cycle arrest and apoptosis, consequent upon short-term TERT inhibition, were associated with and likely
dependent on the activation of the DNA damage response (DDR), highlighted by the increased levels of γH2AX and activation of
ATM and ATR pathways. Analyses of the mean and range of telomere lengths and telomere dysfunction-induced foci indicated that
DDR after short-term TERT inhibition was not related to telomere dysfunction, thus suggesting that TERT, besides stabilizing
telomere, may protect DNA via telomere-independent mechanisms. Notably, TERT-positive LCLs treated with BIBR in combination
with fludarabine or cyclophosphamide showed a significant increase in the number of apoptotic cells with respect to those treated
with chemotherapeutic agents alone. In conclusion, TERT inhibition impairs cell cycle progression and enhances the pro-
apoptotic effects of chemotherapeutic agents in TERT-positive cells. These results support new therapeutic applications of TERT
inhibitors in EBV-driven B-cell malignancies.
Cell Death and Disease (2016) 7, e2562; doi:10.1038/cddis.2016.425; published online 29 December 2016
Telomerase is a ribonucleoprotein complex containing a
catalytic protein with telomere-specific reverse transcriptase
(TERT) activity, which synthesizes telomeric sequences
de novo utilizing an internal RNA template.When the telomere
reaches a critical length because of end-replication problems
of DNA polymerase, cells cease to proliferate and undergo
senescence. Maintenance of telomere length by telomerase is
critical for overcoming replicative senescence and acquiring
unlimited replicative potential.1,2 In humans, TERT is the
rate-limiting component of the telomerase complex3 and its
expression, usually absent in normal somatic cells, is
detectable in most cancer cells.4
Recent studies have suggested that, besides maintaining
telomere length, TERT is involved in other cellular functions of
biological relevance.5 In fact, in vitro evidence indicates that
TERT prevents cell cycle arrest and confers protection from
apoptosis induced by adverse culture conditions6 and DNA-
damaging agents,7 prevents cell growth arrest induced by
retinoic acid in promyelocytic leukemia-derived cell lines,8
antagonizes p53-induced apoptosis in Burkitt's lymphoma
(BL) cells9 and inhibits apoptosis induced by tumor necrosis
factor (TNF)-α.10
TERT expression also affects the latent/lytic status of
Epstein–Barr virus (EBV) in EBV-positive B
lymphocytes.11,12 EBV is a ubiquitous human gamma
herpesvirus causally linked to the development of several
malignancies including BL, Hodgkin's lymphoma, post-
transplant lymphoprolipherative disorders and AIDS-
associated lymphomas.13 EBV has a potent transforming
capacity, and efficiently in vitro induces uncontrolled prolifera-
tion of infected B lymphocytes and generate immortalized
lymphoblastoid cell lines (LCLs), which are a suitable in vitro
model of EBV-driven B-cell lymphomas, mainly those arising
in immunocompromised patients. Like many other tumors,
EBV-associated malignancies maintain their ability to grow
indefinitely through inappropriate activation of telomerase.
The latent membrane protein 1 (LMP1), the major EBV
oncoprotein, activates the TERT promoter at the transcrip-
tional level via nuclear factor kappa B and MAPK/ERK1/2
pathways and increases telomerase activity in B
lymphocytes.14 In addition, it has been reported that cells
newly infected by EBV exhibit signs of telomere dysfunction
and chromosomal rearrangements, mainly due to EBV-
mediated displacement of shelterin proteins and uncapping
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problem at telomeres;15,16 however, established LCLs show
minimal or no signal of telomere dysfunction and have a stable
karyotype.15,16
Given the ample spectrum of critical functions modulated
by TERT, its inhibition could represent a promising
strategy to improve cancer treatment, regardless of telomere
length. In fact, TERT inhibition in different cellular back-
grounds is associated with cell growth arrest, induction of
apoptosis7,17–19 and increased sensitivity to ionizing
radiation.18 Our previous work has demonstrated that TERT
inhibition by short hairpin RNA triggers the complete viral lytic
cycle and cell death in EBV-positive cells.12
In the growing list of promising anticancer drugs, BIBR1532
(BIBR), a synthetic non-nucleoside compound, can be
regarded as one of the most potent specific inhibitors of
TERT.20,21 This drug targets the catalytic activity of the
telomerase enzyme by binding directly to the telomerase core
component thereby reducing the affinity for deoxyribonucleo-
tides (dNTPs). The drug's and TERT-binding sites for dNTPs
are close or even overlap, thus creating reciprocal steric
interference in binding efficiency.22,23 It has been demon-
strated that in long-term cultures of human cancer cells of
different histological origin, low doses of BIBR can induce a
senescence phenotype associated with telomere shortening,
which confirms the drug's ability to inhibit canonical TERT
activity on telomere.22,24–27 It has also been demonstrated that
short-term treatment with high doses of BIBR induces
cytotoxicity in leukemia cells,27,28 most probably by directly
inducing telomere dysfunction.27 No data are as yet available
concerning the effects of BIBR on EBV-immortalized LCLs
and transformed BL cell lines.
On these grounds, we carried out this study aimed at
characterizing the effects of BIBR in LCLs and BL cell lines.
The impact of BIBR combined with fludarabine (FLU) or
cyclophosphamide (CY) treatment on LCL viability, cell cycle
profile and apoptosis was also evaluated. The study's ultimate
aim was to provide a rationale supporting the inclusion of
TERT inhibitors in treatment schedules for EBV-driven B-cell
malignancies.
Results
TERT inhibition by BIBR. 4134/Late and 4134/TERT+
LCLs were positive for TERT mRNA, protein expression
and telomerase activity, whereas 4134/TERT- cells were not
(Figures 1a–c). The telomeric repeat amplification protocol
(TRAP) assay, carried out by adding 2 μM BIBR to protein
extracts of TERT-positive 4134/Late and 4134/TERT+ cells,
demonstrated that BIBR efficiently inhibits telomerase activity
in both TERT-positive cell lines (Figure 1d). Similar results
were obtained in TERT-positive BL41 and BL41/B95.8 BL
cells (data not shown).
The LCLs were then exposed to varying concentrations
(from 10 to 60 μM) of BIBR and analyzed for cell viability at 16,
24, 36, 48 and 72 h (Supplementary Figure 1). Treatment with
BIBR at 30 μM resulted in decreased proliferation rates of
TERT-positive cells at all time points, whereas no effect was
seen in TERT-negative 4134/TERT- and U2OS cells. Similar
results were reached in the EBV-negative BL41 and its EBV-
positive counterpart BL41/B95.8 BL cell lines (Supplementary
Figure 1). At 60 μM, even the TERT-negative cell cultures
(4134/TERT- and U2OS) showed reduced proliferation rates
compared with untreated controls (Supplementary Figure 1).
Figure 1 TERTexpression and activity in LCLs. (a) Levels of TERT transcripts in 4134/TERT-, 4134/Late and 4134/TERT+ LCLs. Means and S.D. (bar) of values from three
independent experiments are shown. (b) Expression of TERT protein and housekeeping α-tubulin in LCLs assessed by western blotting. (c) Telomerase activity tested by TRAP
assay in telomerase-negative U2OS and 4134/TERT- cells and in telomerase-positive 4134/Late and 4134/TERT+ cells. Panels from one representative experiment are shown.
(d) In vitro efficiency of BIBR tested by TRAP assay in telomerase-positive 4134/Late and 4134/TERT+ by addition of BIBR (2 μM) or DMSO as control in protein extracts. Panels
from one representative experiment are shown. TL, telomerase ladder; ITAS, internal telomerase assay standard
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The concentration of 30 μM was then used for experiments in
all cell lines.
BIBR induces S-phase accumulation of TERT-positive
LCLs and BL cells. We have previously demonstrated that
TERT knockdown by short hairpin RNA induces cell cycle
perturbations in both EBV-positive and EBV-negative lym-
phoma B cells.12 TERT-positive 4134/Late and 4134/TERT+
cells treated with BIBR also showed alterations in cell cycle
profile, with decreased cells in the G1-phase, disappearance
of the G2/M-phase and a significant accumulation of cells in
the S-phase (Figure 2). In particular, the S-phase was
Figure 2 Effect of TERT inhibition by BIBR on cell cycle profiles in LCLs and BL cells. Cells, treated with BIBR (30 μM) and DMSO as control at 16, 24 and 48 h, were labeled
with PI and analyzed by flow cytometry for cell cycle distribution. Panels from one representative experiment are shown. Percentages of cells in G1, S and G2/M-phase are shown
in graphs below. Black bars: BIBR-treated cells; gray bars: DMSO-treated control cells. Values are means and S.D. (bar) of three separate experiments. Significant differences
between values in BIBR-treated versus DMSO-treated cells are shown: *Po0.05, **Po0.01 and ***Po0.001
Figure 3 Effect of TERT inhibition by BIBR on cell viability in LCLs and BL cells. Cells treated with BIBR (30 μM) and DMSO at 24, 48 and 72 h, were labeled with annexin V/
PI and analyzed by flow cytometry for cell viability. Panels from one representative experiment are shown. Percentages of specific cell death were calculated as described in
Materials and Methods section, with DMSO-treated samples as controls. Values are means and S.D. (bar) of three separate experiments. Significant differences between values
in BIBR-treated versus DMSO-treated cells are shown. *Po0.05, **Po0.01 and ***Po0.001
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significantly increased compared with dimethylsulfoxide
(DMSO)-treated control cells in both cell cultures, particularly
at 16 and 24 h of exposure. Similar findings were observed in
both EBV-negative BL41 and EBV-positive BL41/B95.8 BL
cells; at 24 h of exposure, both cell lines showed a significant
increase of cells in S-phase compared with DMSO-treated
control cells (Figure 2). Instead, BIBR treatment did not affect
the cell cycle profile of 4134/TERT- (Figure 2) and U2OS cells
(Supplementary Figure 2A).
Consistently, the expression of the protein ribonucleotide
reductase RNR-R2, a molecular marker of the S-phase, was
higher in BIBR-treated TERT-positive LCLs than in untreated
controls, whereas 4134/TERT- BIBR-treated cells showed no
RNR-R2 upregulation (Supplementary Figure 3). These
findings, taken together, support the hypothesis that BIBR
can affect cell cycle progression by promoting selective
accumulation of cells in the S-phase in TERT-positive B cells.
TERT inhibition leads to apoptosis in TERT-positive LCLs
and BL cells. As previous data had indicated that BIBR can
promote apoptosis,27,28 we analyzed the pro-apoptotic effects
of this drug in both LCL and BL models. TERT-positive LCLs
treated with 30 μM BIBR showed a progressive increase in
the number of apoptotic cells compared with controls at all the
time points considered (Figure 3). Similar results were
observed in BL41 and BL41/B95.8 cells treated with BIBR;
a significant increase in the number of apoptotic cells
compared with controls was observed at 48 h of exposure,
and the rate of apoptotic cells was higher in BL41/B95.8 than
BL41 cells (Figure 3). Conversely, 4134/TERT- (Figure 3) and
U2OS cells (Supplementary Figure 2B) exposed to BIBR
showed no increase in the number of apoptotic cells.
TERT inhibition activates the ATM/ATR cascade. To shed
light on the possible mechanism underlying the cell cycle
arrest and apoptosis consequent upon TERT inhibition by
BIBR, we studied the involvement of the ATM and ATR
pathways, which are critical regulators of cell cycle progres-
sion and apoptosis. BIBR treatment resulted in increased
levels of the phosphorylated active form of ATM and ATR and
their downstream substrates CHK1, CHK2 and pro-apoptotic
p53 protein in 4134/Late and 4134/TERT+ cells, as well as in
both EBV-negative BL41 and EBV-positive BL41/B95.8 cell
lines (Figure 4). Conversely, no changes in the phosphoryla-
tion level of these proteins were noted in 4134/TERT- and
U2OS cells (Supplementary Figure 4). Thus, TERT inhibition
activates ATM and ATR cascades in TERT-positive LCLs and
BL cells.
TERT inhibition leads to H2AX activation in TERT-
positive LCLs and BL cells. ATM and ATR are the key
sensors of DNA damage.29 Findings that both these proteins
are activated in BIBR-treated TERT-positive cells suggested
that TERT inhibition could induce DNA damage and activate
the DNA damage response (DDR). To assess this possibility,
cells were stained for γH2AX, a marker of DNA damage.30 As
shown in Figure 5a, TERT-positive 4134/Late, 4134/TERT+,
BL41 and BL41/B95.8 cells showed a significant increase in
γH2AX-positive cells, even after 24 h of exposure (Figure 5a).
Conversely, 4134/TERT- and U2OS cells exposed to BIBR
showed no evidence of increased DNA damage. The γH2AX
mean fluorescence intensity (MFI) also increased signifi-
cantly in TERT-positive BIBR-treated cell lines compared with
DMSO-treated control ones, whereas in TERT-negative cells
no differences in MFI levels were observed between cells
treated with BIBR or DMSO (Figure 5b).
Figure 4 TERT inhibition activates the ATM and ATR cascades. TERT inhibition by BIBR results in activation of ATM/ATR pathways in 4134/Late, 4134/TERT+, BL41 and
BL41/B95.8 cell lines. Cells were treated with BIBR (30 μM) and analyzed after 36 h of exposure by western blot. Phospho-ATM (p-ATM), phospho-ATR (p-ATR), phospho-CHK1
(p-CHK1), phospho-CHK2 (p-CHK2), phospho-p53 (p-p53) and p53 (p53) protein expression, detected by specific antibodies, are shown. Graphs on right: densitometry analysis
in arbitrary units performed with ImageJ software (NIH, Bethesda, MD, USA), with value of 1 assigned to DMSO-treated control samples. Gray bars: BIBR-treated cells; black
bars: DMSO-treated control cells
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Short-term inhibition of TERT does not affect telomere.
Replicative telomere attrition leads to activation of ATM and
ATR. To elucidate whether the DDR in BIBR-treated cells can
be activated by telomere erosion, we assessed the effects of
the drug on telomere length. BIBR treatment did not affect the
telomere length of LCLs or BL cells, as measured by
quantitative multiplex PCR at 72 h of exposure (Figure 6a).
This finding was confirmed by terminal restriction fragment
(TRF) analysis (Figure 6b). Unlike the PCR-based assay,
which gives a mean estimate of telomere length of the cellular
population, TRF makes it possible to visualize the range of
telomere length. The results showed that the TRF ranges are
the same in cells treated with BIBR or DMSO, thus excluding
the possibility that BIBR selectively targets cells with short
telomeres within one cellular population.
It has been demonstrated that EBV infection may cause
telomere dysfunction, mainly due to reduction and displace-
ment of TRF2 shelterin protein from telomeres; however, this
effect was greatly reduced in LCLs kept in culture for an
extended period of time.15,16 In agreement with these
observations in established LCLs, in our 4134/Late cells,
combined telomere FISH/TRF2 immunofluorescence showed
that TRF2 was expressed and localized on telomeres
(Supplementary Figure 5B). In addition, the treatment of
4134/Late cells with 30 μM BIBR at 24 h did not modify the
expression and localization of TRF2 protein compared with
DMSO control cells (Supplementary Figures 5A and 5B).
These results suggest that DDR is not driven by TRF2
displacement and uncapping problems at telomeres. To
elucidate in greater detail whether DNA damage is associated
with telomeres, we examined the presence of telomere
dysfunction-induced foci (TIF) in cells exposed to BIBR. Most
of the γH2AX foci, markers of DNA damage, did not colocalize
with telomere probe signals, and the number of TIF per
nucleus was always lower than 3 (Figure 6c). All together,
these findings indicate that inhibition of TERT by BIBR may
lead to DNA damage randomly rather than specifically on
telomeres.
Effects of combined treatment with BIBR and FLU or
CY. The observation that TERT inhibition by BIBR leads to
cell cycle arrest and apoptosis prompted us to investigate
whether TERT inhibition increases susceptibility to antineo-
plastic drugs. We therefore examined the effects of
BIBR in combination with FLU or CY, two of the agents
most frequently used to treat B-cell malignancies, in the
LCL model.
Each drug was used alone or in combination with BIBR.
Cells exposed to FLU were analyzed at 48 and 72 h
(Figure 7a). In both 4134/Late and 4134/TERT+, treatment
with FLU alone did not modify the cell cycle profile, whereas
cells treated with BIBR+FLU showed a significant increase of
cells in the S-phase and a decrease in the G1-phase, at both
48 and 72 h. Conversely, in 4134/TERT- cells, neither
Figure 5 TERT inhibition by BIBR increases DNA damage in TERT-positive cells. (a) TERT-positive 4134/Late, 4134/TERT+, BL41 and BL41/B95.8 cells and TERT-negative
4134/TERT- and U2OS cells exposed for 24 h to BIBR or to DMSO as control, were stained with γH2AX to evaluate DNA damage and analyzed by flow cytometry. Panels from
one representative experiment are shown. (b) Levels of γH2AX MFI in BIBR- and DMSO-treated cells. Significant differences between values in BIBR-treated versus DMSO-
treated cells are shown: *Po0.05, **Po0.01 and ***Po0.001
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treatments with FLU alone or FLU+BIBR induced significant
cell cycle changes (Figure 7a).
Cells treated with FLU and FLU+BIBR were also analyzed
for apoptosis. 4134/TERT- cells were more sensitive to FLU
alone (apoptosis of 29±2% at 72 h) than 4134/Late cells
(14±2% at 72 h) and 4134/TERT+ cells (3±1% at 72 h)
(Figure 7b). In 4134/Late and 4134/TERT+ cells, BIBR+FLU
treatment significantly increased the percentage of apoptotic
cells compared with that obtained with FLU alone. In contrast,
BIBR+FLU treatment of TERT-negative cells did not increase
the number of apoptotic cells compared with that obtained with
FLU alone (Figure 7b).
Parallel experiments were performed with CY alone or in
combination with BIBR. Cell cycle profiles were analyzed at 24
and 48 h in all LCLs (Figure 8a). In 4134/Late and 4134/TERT+,
CY induced a decrease of cell number in G1-phase at 48 h,
whereas in 4134/TERT- cells CY treatment slightly increased
cell number in the S-phase. Treatment with BIBR+CY in TERT-
positive cells induced complete arrest of the cell cycle, whereas
in 4134/TERT- the pattern observed with BIBR+CY had no
effect compared with cell cultures treated with CY alone
(Figure 8a). The number of apoptotic cells after exposure to
CY alone was higher in 4134/Late (47±4% at 48 h) than in
4134/TERT- cells (21±2%) (Figure 8b). In 4134/Late and
4134/TERT+ cells treatment with BIBR+CY significantly
increased the apoptotic effect compared with those obtained
withCYalone, whereas BIBR+CYdid not change the number of
apoptotic cells compared with that obtained with CY alone in
4134/TERT- cell culture (Figure 8b).
Discussion
In this study, we demonstrate that in TERT-positive LCLs
short-term TERT inhibition by BIBR causes cell cycle arrest,
accumulation of cells in the S-phase and apoptosis. Similar
results were obtained in the BL41 and its EBV convertant
BL41/B95.8 BL cell lines. These effects driven by BIBR were
telomerase-specific, as they were not observed in telomerase-
negative LCL 4134/TERT- and U2OS cells.
This study provides evidence indicating that cell cycle arrest
and apoptosis induced by BIBR-mediated TERT inhibition are
related and probably dependent on the activation of the DDR
pathway. In particular, TERT inhibition induces DNA damage,
highlighted by increased levels of γH2AX, resulting in the
Figure 6 Short-term TERT inhibition by BIBR did not affect telomere. TERT-positive 4134/Late, 4134/TERT+, BL41 and BL41/B95.8 cells and TERT-negative 4134/TERT- and
U2OS cells exposed for 72 h to BIBR or to DMSO as control were analyzed for telomere length. (a) Telomere length measured by quantitative multiplex PCR assay. TS values are
e means and S.D. (bar) of three separate experiments. (b) Telomere lengths analyzed by TRF by the TeloTAGGG telomere length assay. Panel from one representative
experiment is shown. (c) TIF analysis. Representative micrographs showing combined telomere FISH/γH2AX immunofluorescence of 4134/Late cells treated with BIBR at 24 h.
From the left: DAPI (nuclear marker, blue), telomere probe (red), γH2AX (DNA damage marker, green), combined Telomere/γH2AX and the merged image. Scale bar: 2 μm
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activation of DDR and phosphorylation of the ATM and ATR
kinases, which in turn activate the mitotic checkpoints CHK1,
CHK2 and the pro-apoptotic p53 protein to induce cell cycle
arrest with accumulation of cells in the S-phase and apoptosis.
Notably, in the EBV-positive BL41/B95.8 cells, the inhibition of
TERT by BIBR leads to an earlier and greater accumulation of
cells in the S-phase, as well as a higher number of apoptotic
cells, than in the EBV-negative counterpart BL41 cells. This
effect may be due to the underlying EBV infection and in
particular to the effects consequent upon TERT inhibition in
this cellular background. In fact, it has been demonstrated that
the EBV protein BGLF4 can directly promote elongation of the
S-phase.31 Intriguingly, this protein is expressed during the
EBV lytic cycle and we have previously demonstrated that
TERT inhibition in EBV-infected cells triggers a complete viral
lytic replication.12 From a therapeutic perspective, these
findings suggest that TERT inhibition may induce more
pronounced effects of potential relevance in EBV-associated
lymphoproliferations as compared with EBV-unrelated B-cell
malignancies.
It is well-known that shelterin proteins binding to telomeres
enable cells to distinguish their chromosome ends from DNA
breaks and to repress DNA repair reactions.32,33 Replicative
telomere attrition with depletion of TRF2 and POT1 shelterin
proteins leads to activation of both ATM- and ATR-mediated
DDR.34 Notably, it has been demonstrated that EBV in newly
infected cells may cause telomere dysfunction, mainly due to
decreased expression of shelterin proteins and displacement
of TRF2 from telomeres;15,16 in addition, the EBV-encoded
LMP1 transfected in EBV-negative BL cells promotes down-
regulation of shelterin proteins.35 However, in agreement with
previous observations on established LCLs,15,16 we did not
find any TRF2 displacement from telomeres in our LCL cells.
Nakashima et al.24 have reported that long-term BIBR
treatment of HeLa-EM2-11ht cells is associated with telomere
shortening and activation of DDR at telomeres. Telomere
shortening after long-term BIBR treatment has also been
reported in chronic myeloid leukemia cells25 and in human
promyelocytic leukemia cells.26 Besides these results sup-
porting the ability of BIBR to inhibit the canonical TERTactivity
Figure 7 Effects of FLU and BIBR+FLU treatments on cell cycle profiles and cell viability in LCLs. Cells were treated with FLU (5 μM) and BIBR (30 μM) plus FLU (5 μM)
(BIBR+FLU) and analyzed at 48 and 72 h. DMSO was used as control. (a) Cells were labeled with PI and analyzed by flow cytometry. Panels from one representative experiment
are shown. Graphs on right: percentages of cells in G1-, S- and G2/M-phase. Values are means and S.D. (bar) of three independent experiments. (b) Cells were labeled with
annexin V/PI and analyzed by flow cytometry. Panels from one representative experiment are shown. Graphs on right: percentages of specific cell death. Values are means and S.
D. (bar) of three separate experiments. Significant differences between values in BIBR+FLU-treated versus FLU-treated cells are shown: *Po0.05, **Po0.01 and ***Po0.001
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on telomeres during long-term treatment, it has been reported
that high doses of BIBR induced growth arrest and apoptosis
in short-term culture assays in both leukemia cell lines and
primary cells from patients with acute myeloid leukemia and
chronic lymphocytic leukemia.27 Notably, similar findings were
also observed in cells without detectable telomerase activity,
and the authors suggested that they were due to direct
damage by high doses of BIBR on telomere structures, being
thus independent of telomerase.27
In our in vitro models, the DDR pathway activated after
short-term exposure to low doses of BIBR seemed to be
substantially unrelated to telomere dysfunction, being instead
dependent on TERT inhibition per se, as none of above effects
were observed in TERT-negative cells. BIBR-treated cells
have exactly the same mean telomere length, estimated by
multiplex PCR, and range, estimated by TRF analysis, as
control DMSO-treated cells. In addition, BIBR treatment did
not modify the expression and telomere localization of TRF2,
which is compatiblewith the persistence of its capping function
on telomeres. The diffuse localization of γH2AX foci and the
limited number of TIF in BIBR-treated cells clearly
demonstrated that the DNA damage induced by TERT
inhibition in short-term experiments was randomly rather than
specifically localized on telomeres.
Thus, the findings that TERT inhibition determines DNA
damage, unrelated to telomere dysfunction, reinforces the
concept that TERT may have additional roles other than
maintaining telomere length, and are in line with the growing
body of data describing the extra-telomeric functions of
telomerase in many biological processes, including cellular
proliferation, gene expression regulation, DNA repair process
and mitochondrial functionality.5,36 In particular, several lines
of evidence demonstrate that TERT is partially targeted to
mitochondria, in which it may influence the production of
reactive oxygen species (ROS), and thus DNA damage and
apoptosis.37–39 TERT is also involved in DNA repair
processes,40,41 and TERT inhibition may lead to perturbation
of chromatin structure with diminished capacity for DNA repair
and thus accumulation of DNA damage.41 On these grounds,
the DNA damage we observed after short-term TERT
inhibition may be due to increased ROS levels and/or
perturbation of the chromatin structure. Further studies are
Figure 8 Effects of CYand BIBR+CY treatments on cell cycle profiles and cell viability in LCLs. Cells were treated with CY (4 mM) and BIBR (30 μM) plus CY (4 mM) (BIBR
+CY) and analyzed at 24 and 48 h. DMSO was used as control. (a) Cells were labeled with PI and analyzed by flow cytometry. Panels from one representative experiment are
shown. Graphs on right: percentages of cells in G1-, S- and G2/M-phase. Values are means and S.D. (bar) of three separate experiments. (b) Cells were labeled with annexin V/PI
and analyzed by flow cytometry. Panels from one representative experiment are shown. Graphs on right: percentages of specific cell death. Values are means and S.D. (bar) of
three independent experiments. Significant differences between values in BIBR+CY-treated versus CY-treated cells are shown: *Po0.05, **Po0.01 and ***Po0.001
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warranted to define themechanisms underlying the short-term
consequences of TERT inhibition unrelated to telomere
dysfunction.
In the light of the possible integration of TERT inhibitors in
chemotherapeutic regimens, we treated the LCLs with two
drugs used in manage lymphoproliferative disorders (FLU and
CY), both alone and in combination with BIBR. Notably,
treatment with FLU alone did not alter the cell cycle profile and
induced more pronounced apoptotic effects in TERT-negative
than in TERT-positive cells. These observations support the
finding that high TERT levels confer protection against
apoptosis.7,26 Indeed, TERT inhibition does sensitize cells to
the drug-induced apoptotic effect, as demonstrated by the
high number of apoptotic cells induced by BIBR+FLU in TERT-
positive cell cultures. Consistently, the percentage of apoptotic
cells in 4134/Late culture treated with BIBR+FLU at 72 h was
similar to that observed in 4134/TERT- cell culture treated with
FLU alone.
CY alone induced stronger apoptotic effects in TERT-
positive than in TERT-negative cells; this is consistent with
its effect in proliferating cells, taking into account the fact that
TERT-positive cells proliferated more rapidly than TERT-
negative cells. Nonetheless, the addition of BIBR caused cell
cycle arrest and an increased apoptotic effect in TERT-
positive cells.
Our findings support the concept that inhibition of the extra-
telomeric functions of TERT could be exploited as an effective
therapeutic strategy for a variety of tumors, including B-cell
malignancies, regardless of telomere length. The inclusion of
telomerase inhibitors in chemotherapy protocols for cancer
patients may have strong effects on cell proliferation and
survival and thus may represent a valid strategy to comple-
ment current treatment modalities, as also suggested by
others.42,43 Confirmation of these findings in primary tumors
cells from patients with EBV-driven and unrelated B-cell
malignancies and in suitable animal models will pave the
way for a solidly based pre-clinical rationale for including TERT
inhibitors in chemotherapy protocols for the treatment of these
malignancies.
Materials and Methods
Cell lines. The 4134 LCL was obtained by infecting peripheral blood
mononuclear cells from normal donor with the B95.8 EBV strain. Establishment
and characterization of this cell line has already been described.11 4134/TERT- and
4134/Late cells were derived from early and late passages after EBV infection and
expressed very low and high level of endogenous TERT, respectively.11,44 The 4134/
TERT+ cell line, expressing ectopic TERT, was obtained by infecting 4134/TERT-
cells with a retroviral vector.11 All three 4134 cell lines used in this study were
negative for BZLF1 and viral lytic proteins EA-D and gp350. BL41 is an EBV-
negative BL cell line with translocated MYC gene (kindly provided by Martin Rowe,
Cancer Center, University of Birmingham, Birmingham, UK). BL41/B95.8 is the
counterpart cell line infected in vitro with the B95.8 EBV strain (kindly provided by
Martin Allday, Ludwig Institute for Cancer Research, London, UK). LCLs and BL41
were cultured in RPMI-1640 medium (Euroclone, Milano, Italy), supplemented with
glutamine 4 mM, 50 mg/ml gentamycin (Sigma-Aldrich, St. Louis, MO, USA) and
10% heat-inactivated fetal bovine serum FBS (Gibco, Milano, Italy; standard
medium) at 37 °C and 5% CO2. BL41/B95.8 cells were grown in standard medium
supplemented with 1 mM sodium pyruvate, 1% nonessential amino acids (Sigma-
Aldrich), and 50 mM β-mercaptoethanol. The human osteosarcoma cell line U2OS
was used as TERT-negative control;45,46 cells were maintained in McCoy’s 5A
medium modified (Thermo Fisher Scientific, Waltham, MA, USA), supplemented
with 10% fetal bovine serum (Gibco). Cell lines were checked and controlled by
cytogenetic analyses. All cell lines were tested and resulted negative for
mycoplasma contamination.
Compounds. A stock solution of BIBR (Selleck Chemicals LLC, Houston, TX,
USA) at a concentration of 10 mM was prepared by dissolving the compound in
sterile DMSO, divided into aliquots and stored at − 80 °C until use. FLU (F9813;
Sigma-Aldrich) was prepared by resuspending the compound in DMSO at a
concentration of 10 mM, divided into aliquots and stored at − 20 °C until use. CY
(C0768; Sigma-Aldrich) was prepared by dissolving the compound in sodium
chloride 0.9% solution at a concentration of 360 mM, divided into aliquots and
stored at 4 °C. It was warmed to 37 °C for 30 s, immediately before use.
LCLs were exposed to serial dilution of FLU and CY to identify the half-maximal
inhibitory concentration (IC50) (Supplementary Figure 6). Optimal molarity was
defined on the basis of the observed effects on the most sensitive cell line to each
drug. FLU for 4134/TERT- had an IC50 concentration of 5 μM. CY on 4134/Late
exhibited 50% of cell survival at a concentration of 4 mM. These concentrations were
used for all drug experiments.
Real-time PCR for quantification of TERT transcripts. Cellular RNA
was extracted and retrotranscribed into cDNA, as previously detailed.11 TERT
transcripts were quantified by real-time PCR, with the AT1/AT2 primer pair, as
previously described.11,47
Analysis of telomerase activity. For each sample, three million cells were
lysed in 50 μl of CHAPS buffer (0.5% CHAPS, 10 mM TrisHCl, pH 7.5, 1 mM
MgCl2, 1 mM EGTA, 0.1 mM phenylmethyl-sulfonyl fluoride, 5 mM β-mercaptoetha-
nol, 10% glycerol) and incubated at 4 °C for 30 min. The lysate was then
centrifuged at 12000 g for 30 min at 4 °C and the supernatant collected. Telomerase
activity was assessed by the PCR-based TRAP, as previously reported.48 The
TRAP assay was performed with 0.250 μg of total cell lysate.
Western blotting. Western blot analyses from cell cultures were prepared as
previously reported.49 The expression of TERT, RNR-R2, TRF2 and α-tubulin was
evaluated by anti-TERT (ab94523, Abcam, Cambridge, UK), anti-RRM2/RNR-R2
(B-Bridge International, Cupertino, CA, USA), anti-TRF2 (Novus Biological, Littleton,
CO, USA) and anti-α-tubulin (Sigma-Aldrich) antibodies (Ab), respectively. The ATM
and ATR pathways were examined with specific Ab against the phosphorylated/
active form of ATM (ab81292, Abcam), ATR (ab178407, Abcam), CHK1 (ab195753,
Abcam), CHK2 (ab195929, Abcam), p53 (9284, Cell Signaling, Danvers, MA, USA)
and un-phosphorylated form of p53 (sc-6243, Santa Cruz Biotechnology, Dallas, TX,
USA). Blots were incubated with an appropriate peroxidase-conjugated secondary
antibody (Sigma-Aldrich) and stained with a chemiluminescence detection kit
(SuperSignal West Pico Chemiluminescent Substrate, Pierce, Rockford, IL, USA).
α-Tubulin was used as control for loading.
Viability, apoptosis and cell cycle analysis. Cell viability was
determined by Trypan blue exclusion in a Countess automated cell counter
(Invitrogen, Carlsbad, CA, USA). To evaluate cell cycle distribution, cells were
harvested and processed as previously described.12 Samples were analyzed by
flow cytometry (FACS Calibur; Becton-Dickinson, Franklin Lakes, NJ, USA) and cell
cycle profiles were analyzed with ModFit LT Cell Cycle Analysis software (version
2.0) (Verity Software House, Topsham, ME, USA). Apoptosis was evaluated by
staining cells with annexin V and propidium iodide (PI; Sigma-Aldrich), as previously
detailed,12 and analyzed by flow cytometry. At least 50 000 events were acquired;
data were processed with CellQuestPro software (Becton-Dickinson), and analyzed
by Kaluza Analyzing Software v1.2 (Beckman Coulter, Pasadena, CA, USA).
Annexin V-positive/PI-negative and annexin V-positive/PI-positive samples were
classified as early and late apoptotic cells, respectively; both fractions were
considered apoptotic cells. The percentage of specific cell death was estimated with
the following formula: % cell death= 100 x (percentage of dead cells in treated
sample – percentage of dead cells in control)/(100% – percentage dead cells in
control).
Analysis of DDR. Approximately 1 × 106 cells were stained for 1 h in the dark
with the labeled monoclonal antibody for γH2AX (Alexa Fluor 488 mouse anti-H2AX
(pS139), clone N1-431, Becton-Dickinson). Samples were analyzed by flow
cytometry (FACS Calibur, Becton-Dickinson). A total of 30 000 events were
collected according to morphological parameters (forward- and side-scatter).
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Analysis was performed with Kalusa software (Beckman Coulter). The MFI was
measured by BD FACSDiva software (Becton-Dickinson).
Combined FISH/immunofluorescence. 4134/Late cells were harvested
following standard cytogenetic's procedure. Hypotonic treatment was carried out
with 0.075 M KCl at 37 °C for 30 min and the resulting pellets were fixed with
Carnoy's fixative (methanol/acetic acid 3 : 1). Slides were prepared by dropping the
fixative on to wet glass slides and were left to dry overnight at room temperature.
The slides were treated with pepsin 0.5 mg/ml (Sigma-Aldrich) at 37 °C for 15 min.
Telomeres were visualized with the Telomere PNA FISH Kit/Cy3 (DAKO, Glostrup,
Denmark). After digestion, slides were dehydrated by consecutive 2 min in 80, 96
and 100% ethanol and air-dried. Ten microliters of probe was added and a
denaturation step was performed at 80 °C for 5 min, followed by 2 h of hybridization
at room temperature in the dark. Post-hybridization washes were done at 65 °C for
5 min and briefly at room temperature in PBS. Slides were then blocked with 0.2%
fish gelatin and 0.5% BSA in PBS (PBG buffer).50 To visualize TRF2 location slides
were incubated for 1 h with a rabbit polyclonal anti-TRF2 antibody (1 : 1000, Novus
Biological) in PBG buffer followed by Alexa Fluor 488 anti-rabbit (Thermo Fisher
Scientific) in PBG buffer. To visualize DNA damage foci, slides were incubated for
1 h with a mouse monoclonal anti-γH2AX antibody (1 : 1000, Merck Millipore,
Darmstadt, Germany) in PBG buffer, followed by Alexa Fluor 488 anti-mouse
secondary antibody (Thermo Fisher Scientific) in PBG buffer. After washing, slides
were air-dried and mounted with DAPI/antifade solution (250 ng DAPI/aml Antifade
Solution, MetaSystems, Altlussheim, Germany). Microscope analysis were carried
out on a fluorescence microscope (Zeiss Imager. Z2, Oberkochen, Germany)
equipped with a single band filter for DAPI, Cy3 and FITC. Digital images were
captured with CCD camera (iAi CV-M4+CL, Rohs, Yokohama, Japan) using ISIS
software (MetaSystems, Heidelberg, Germany) and Z-stacking function with EC
PLAN-NEUFLUAR × 100 magnification objective. At least 50 nuclei for each
condition were scored in three independent experiments.
Telomere length measurement. Telomere lengths were determined by
quantitative multiplex PCR assay as previously described,51 and by the TeloTAGGG
Telomere Length Assay Kit (Roche Diagnostic GmbH, Basel, Switzerland) according
to the manufacturer's instructions.
Statistical analyses. Statistical analyses were performed with SPSS software
version 21 (IBM, Armonk, NY, USA). Results were analyzed with t-test, ANOVA and
Mann–Whitney test and P-values o0.05 were considered significant.
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